Safety First
Responsibility for 100,000 employees worldwide
Ensuring supplies in difficult times
Our products help to serve basic human needs
Tackling tasks together

We're providing swift, specific and efficient support to ensure medical supplies worldwide
2019: We’ve delivered

Operational targets achieved:
Sales and earnings increased

Strategic targets achieved:
All the announced portfolio measures implemented or agreed upon

Efficiency targets achieved:
Savings and synergies ahead of budget

Ambitious sustainability targets set and anchored

Record investment in research and development
Science for a better life

More than 16,000 employees work in research and development

We collaborate with over 8,000 different partners worldwide
2019: An operationally successful year

Main factors

- Substantial earnings growth due to the acquired agricultural business
- Strong growth in China and for top medicines Xarelto™ and Eylea™
- Sales increase* at Consumer Health, earnings level with prior year

<table>
<thead>
<tr>
<th>Sales (€bn)</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>36.7</td>
<td>43.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clean EBITDA (€bn)</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9.0</td>
<td>11.5</td>
</tr>
</tbody>
</table>
Summer 2019: extreme rainfall in the U.S.

2019: An operationally successful year

Main factors

- Substantial earnings growth due to the acquired agricultural business
- Strong growth in China and for top medicines Xarelto™ and Eylea™
- Sales increase* at Consumer Health, earnings level with prior year

Sales (€bn)

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales (€bn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>36.7</td>
</tr>
<tr>
<td>2019</td>
<td>43.5</td>
</tr>
</tbody>
</table>

Clean EBITDA (€bn)

<table>
<thead>
<tr>
<th>Year</th>
<th>Clean EBITDA (€bn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>9.0</td>
</tr>
<tr>
<td>2019</td>
<td>11.5</td>
</tr>
</tbody>
</table>

* currency- and portfolio-adjusted

Werner Baumann // Annual Stockholders’ Meeting of Bayer AG // April 28, 2020
2020: Good start to the year marked by COVID-19

Hauptfaktoren

Sales and earnings growth in all three divisions

Sharp rise in demand, e.g. for nutritional supplements, due to COVID-19

Also negative impact on parts of the business because of pandemic restrictions

<table>
<thead>
<tr>
<th>Q1 2019</th>
<th>Q1 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales (€bn)</td>
<td></td>
</tr>
<tr>
<td>12.3</td>
<td>12.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q1 2019</th>
<th>Q1 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clean EBITDA (€bn)</td>
<td></td>
</tr>
<tr>
<td>4.0</td>
<td>4.4</td>
</tr>
</tbody>
</table>

+4.8 % (+6.0 %) +10.2 %

( ) currency- and portfolio-adjusted
Current status of glyphosate lawsuits in the U.S.

Courts of first instance have delivered **verdicts against our company in three cases**. None of these verdicts are final.

We continue to engage constructively in the **mediation**. We will only consider a solution that is **financially reasonable** and puts in place a mechanism to resolve potential future claims efficiently.
Outlook for 2020

In this unique crisis, no-one can predict exactly how overall conditions will develop.

Health and nutrition are essential

- The basic supply with health and nutrition is systemically relevant globally.
- This is apparent now as we address the COVID-19 outbreak. Health and nutrition are also essential for tackling the pressing challenge of climate change.
This is the hour of science

- Trust in science and the role of experts has declined in recent years.
- Now people are listening again to researchers’ advice for tackling COVID-19.
Reaching more people

Our vision:

health for all... hunger for none

Health and nutrition for as many people as possible is the key to truly sustainable development

Bayer can be a systemic factor in reaching the United Nations Sustainable Development Goals by 2030
Forward-Looking Statements

This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.